For research use only. Not for therapeutic Use.
PRDX1-IN-1 is a selective inhibtor of PRDX1 with an IC50 value of 0.164 μM. PRDX1-IN-1 can be used in researches related to cancer.PRDX1-IN-1 promots intracellular ROS accumulation, and inhibits the proliferation, invasion and migration of cancer cells besides inducing apoptosis. PRDX1-IN-1 could be used in cancer research[1].
PRDX1-IN-1 inhibites the proliferation activities of the human lung cancer cells A549, lung cancer cell lines (LTEP-a-2 and H1975), human breast cancer cell line (MDA-MB-231), human hepatoma cell line (SK-Hep-1) with the IC50 values of 1.92 μM, 2.93 μM, 1.99 μM, 2.67 μM, 2.42μM, respectively[1].
PRDX1-IN-1 (compound 7e)(2 μM or 4 μM, 24 h) promotes intracellular ROS accumulation, and inhibits the invasion and migration of human lung cancer cells A549[1].
PRDX1-IN-1 (2 μM or 4 μM, 24 h) induces the apoptosis of A549 cells[1].
PRDX1-IN-1 (2 μM or 4 μM, 6 h) suppresses the key signaling pathways (AKT and ERK) and promotes the expression of apoptosis-related proteins (cleaved caspase-3/8 and cleaved PARP) in A549 cells[1].
PRDX1-IN-1 (0.5 or 1 mg/kg, intraperitoneal(i.p.), 19 days, every day) inhibited tumor growth in a mouse model of lung cancer[1].
Catalog Number | I041005 |
Synonyms | [(6aS,6bS,8aS,11R,12aR,14aR)-4,6a,6b,8a,11,14a-hexamethyl-2-oxo-11-[(3,5,6-trimethylpyrazin-2-yl)methylcarbamoyl]-7,8,9,10,12,12a,13,14-octahydropicen-3-yl] (E)-3-phenylprop-2-enoate |
Molecular Formula | C46H55N3O4 |
Purity | ≥95% |
InChI | InChI=1S/C46H55N3O4/c1-28-33-16-17-37-44(7,34(33)25-36(50)40(28)53-39(51)18-15-32-13-11-10-12-14-32)22-24-46(9)38-26-43(6,20-19-42(38,5)21-23-45(37,46)8)41(52)47-27-35-31(4)48-29(2)30(3)49-35/h10-18,25,38H,19-24,26-27H2,1-9H3,(H,47,52)/b18-15+/t38-,42-,43-,44+,45-,46+/m1/s1 |
InChIKey | FRYSNRRDKCJCDD-MAYJLFPOSA-N |
SMILES | CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)NCC6=NC(=C(N=C6C)C)C)C)C)C)C)OC(=O)C=CC7=CC=CC=C7 |
Reference | [1]. Ying Bai, et al. Development of novel celastrol-ligustrazine hybrids as potent peroxiredoxin 1 inhibitors against lung cancer. Eur J Med Chem. 2023, 259, 115656. |